Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

This study has been completed.
Information provided by:
Novartis Identifier:
First received: November 22, 2006
Last updated: February 26, 2009
Last verified: February 2009
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation, when combined with tacrolimus for the first 3 months and with myfortic thereafter.

Condition Intervention Phase
Kidney Transplantation
Drug: AEB071
Drug: Mycophenolic Acid
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: 12-Month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Primary efficacy failure, defined as a composite efficacy endpoint of treated biopsy-proven acute rejection (BPAR), graft loss, death or loss to follow-up [ Time Frame: at 6 months ]

Secondary Outcome Measures:
  • Renal function post-transplant Modification of diet in renal disease (MDRD) formula for Glomerular Filtration Rate) [ Time Frame: at 6 months ]
  • Primary efficacy failure, defined as a composite efficacy endpoint of treated BPAR, graft loss, death or loss to follow-up [ Time Frame: at 3 and 12 months ]
  • Various efficacy endpoints, using treated BPAR, treated acute rejection (AR), death, graft loss, loss to follow-up and combinations thereof. [ Time Frame: at Month 3, 6 and 12 ]
  • Changes in renal function (GFR) after replacing tacrolimus by myfortic in the AEB071 treatment arms [ Time Frame: from Month 3 to Month 6 ]
  • Safety and tolerability [ Time Frame: at 3, 6 and 12 months ]

Enrollment: 215
Study Start Date: October 2006
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Mycophenolic Acid / tacrolimus Drug: Mycophenolic Acid
Experimental: AEB071 / tacrolimus arm 1 Drug: AEB071
Experimental: AEB071 / tacrolimus arm 2 Drug: AEB071


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Male and female patients of any race 18 years or older
  • Adult recipients of a kidney transplant from a deceased or from a living donor
  • Recipients of a functioning Kidney:. Graft must be functional no later than 36h after transplantation.

Exclusion criteria

  • Need for medication prohibited by the protocol
  • Patients or donors infected with hepatitis B or C, or with HIV.
  • Patients with a history of cancer
  • Patients with severe systemic infections Patients with heart diseases (own or family history) which are associated with an increased risk for arrhythmias.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00403416

United States, California
University of California, San Francisco
San Francisco, California, United States, 94143-0780
United States, Ohio
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106-5048
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792-7375
QE II Health Sciences Center
Halifax, Canada, B3H 1V7
Hopital Kremlin Bicetre
Le Kremlin Bicetre, France, 94270
Hopital Hotel Dieu
Nantes, France, 44035
Hopital Necker
Paris, France, 75015
CHU de Rangueil
Toulouse, France, 31403
Universitaetsklinik Charite
Berlin, Germany, 10117
Klinikum der Humboldt Universitat Charite
Berlin, Germany, 13353
Universitaetsklinikum Essen
Essen, Germany, 45122
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Univ. - Klinikum Heidelberg
Heidelberg, Germany, 69120
Staedt. Krankenhaus Koeln-Merheim
Koeln, Germany, 51109
Az. Osp. Di Bologna Polici. S. Orsola - Malpighi
Bologna, Italy, 40138
Azienda Opedaliera Careggi - Universita degli Studi
Firenze, Italy, 50134
Azienda Ospedaliera di Padova - Universita degli Studi
Padova, Italy, 35128
Ciutat Santitaria I Univessitaria de Bellvitge
Hospitalet de Llobregat, Spain, 08907
Hospital 12 de Octubre
Madrid, Spain, 28041
Complejo Hospitalario Carlos Haya
Malaga, Spain, 28041
Hospital Doctor Peset
Valencia, Spain, 46017
Universitatsspital Basel
Basel, Switzerland, 4031
Inselspital Bern
Bern, Switzerland, 3010
Universitätsspital Zürich
Zürich, Switzerland, 8091
United Kingdom
University Hospital of Wales
Cardiff, United Kingdom, CF14 4XW
Western Infirmary
Glasgow, United Kingdom, G11 6NT
Saint George's University of London
London, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00403416     History of Changes
Other Study ID Numbers: CAEB071A2203
Study First Received: November 22, 2006
Last Updated: February 26, 2009

Keywords provided by Novartis:
Mycophenolic acid
Kidney function

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on April 28, 2017